Industry analysts said Pfizer and BioNTech’s $2 billion deal to cover 50 million patients, which is contingent on an approvable product, would likely pressure other manufacturers to set similar prices.
from Hindustan Times - world https://ift.tt/333gdfT
No comments:
Post a Comment